Roche re­turns to Dyno for its AAV tech with $50M up­front

Roche has inked a new deal with Dyno Ther­a­peu­tics to de­vel­op next-gen­er­a­tion AAV cap­sids for gene ther­a­pies tar­get­ing neu­ro­log­i­cal dis­eases, ex­pand­ing the scope of an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER